Tag: Pfizer
-
Pfizer (PFE) Has Become Ridiculously Oversold
Investors may want to keep an eye on Pfizer (PFE). The stock has become ridiculously oversold at double-bottom support dating back to late 2022. RSI, MACD, and Williams’ %R are all oversold, as well. And from a current price of $40.81, we’d like to see PFE run back to $48 initially. We also have to remember…
-
This is Why Pfizer is Still a Buy
Pfizer (PFE) has gone ballistic. Since bottoming out at around $42 in October, the stock is now up to $53.33. From here, it could move even higher on an upgrade from Goldman Sachs. The firm just upgraded PFE to a buy rating with a price target of $60 a share. According to TheFly.com: Goldman Sachs…
-
Shares of Pfizer Just Got a Substantial Boost
There goes Pfizer (PFE). The stock is popping on news it’s buying ReViral – a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV) for $525 million. “Currently, treatment options for RSV are extremely limited and focus primarily on supportive care,” said Annaliesa Anderson,…
-
This is Why Pfizer Just Popped, As We Expected
Pfizer is pushing to higher highs. In fact, as we noted on November 2, “After finding support around $41, the vaccine stock bolted to nearly $46, and could test $47, even $50, near-term. All after the company raised its full-year sales forecast to $36 billion, as it signed deals for booster doses. The stock could…
-
This is Why Shares of Pfizer Could Race Higher
Pfizer is pushing to higher highs. After finding support around $41, the vaccine stock bolted to nearly $46, and could test $47, even $50, near-term. All after the company raised its full-year sales forecast to $36 billion, as it signed deals for booster doses. The stock could push even higher on a US CDC vote.…
-
The Top 3 Vaccine Trades that Should be in All Portfolios
Moderna (MRNA) has been incredibly explosive for us. The first time we highlighted opportunity, the stock traded at $72 on Oct. 20. At the moment, it’s up to $171.92 in pre-market, and we still believe it could rally to $200. For one, “This positive primary analysis confirms the ability of our vaccine to prevent COVID-19…
-
This is Why Moderna Could Run to $200, Near-Term
Vaccine news has created big opportunity. Look at BioNTech for example. The stock exploded from $88.50 to $124.24 after it and Pifzer said its vaccine had a 95% effective rate with no safety concerns. “Efficacy was consistent across age, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%,”Pfizer…
-
Top “Blood in the Streets” Opportunities to Consider
Over the last few months, the pandemic crippled the economy, destroying top stocks. However, with a potential vaccine, those stocks may now be great “blood in the streets” opportunities. All on news Pfizer just said its COVID-19 vaccine is 90% effective. “Amazing news from Pfizer with 90% efficacy. This hopefully is the beginning of the…
-
COVID-19 Vaccine: The Top Two Stocks to Consider Immediately
The pandemic is only getting worse. At the moment, there are nearly 40 million global cases, with 1.1 million deaths. In the U.S., the count is up to 8.14 million. India is up to nearly 75. Million. Brazil is up to 5.2 million. Russia is nearing 1.4 million. Colombia is up to 952,373. In Paris,…
-
The Top 3 COVID-19 Treatment Stocks to Watch
With the coronavirus showing no signs of slowing, the world is in desperate need for a treatment — and fast. Thankfully, we may be nearing potential solutions, which could drive these three stocks even higher. One, shares of OPKO Health (OPK) are picking up a good deal of momentum, as markets wait for news on…